Skip to content

Author

Jing Liu

We have 2 of 33 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Signal Mining of Adverse Events of Antiangiogenic Drugs in Colorectal Cancer Based on the FDA Adverse Event Reporting System (FAERS) Database

Fruquintinib is characterized by a higher proportion of early-onset and potentially unlabeled adverse events, highlighting the need for early and tailored safety monitoring in clinical practice.

Bing Wu, Xin-Ning Yu, Hua-Tao Wu et al. · 0 citations
Aug 2026

The miR-338-5p/METTL3 axis regulates m6A modification to inhibit tumor progression in triple-negative breast cancer.

This study reveals post-transcriptional regulation of METTL3 by miR-338-5p by confirming a functional miR-338-5p/METTL3/m6A axis in TNBC and targeting this distinct regulatory axis represents a promising therapeutic strategy for TNBC.

Wen-Jia Chen, Ya Xu, Yang-Zheng Lan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.